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reproduction in any medium, provided the original author and source are credited.SUMMARYWhether human induced pluripotent stem cells (hiPSCs) are epigenetically identical to human embryonic stem cells (hESCs) has been
debated in the stem cell field. In this study, we analyzed DNAmethylation patterns in a large number of hiPSCs (n = 114) and hESCs (n =
155), and identified a panel of 82CpGmethylation sites that can distinguish hiPSCs fromhESCswith high accuracy.We show that 12 out
of the 82 CpG sites were subject to hypermethylation in part by DNMT3B. Notably, DNMT3B contributes directly to aberrant hyperme-
thylation and silencing of the signature gene,TCERG1L. Overall, we conclude thatDNMT3B is involved in awave of de novomethylation
during reprogramming, a portion of which contributes to the unique hiPSCmethylation signature. These 82 CpGmethylation sitesmay
be useful as biomarkers to distinguish between hiPSCs and hESCs.INTRODUCTION
DNA cytosinemethylation is a major epigenetic factor that
contributes to regulating important biological processes
such as genomic imprinting, X inactivation, and gene regu-
lation. DNA methylation is established and maintained by
a family of DNA methyltransferases (DNMTs), including
DNMT1, DNMT3A, and DNMT3B, and deficiency in any
Dnmt enzyme leads to embryonic death inmice. Addition-
ally, aberrant DNA methylation is associated with human
diseases such as cancer, immunodeficiency, and neurolog-
ical disorders (Feng and Fan, 2009). Collectively, these
observations indicate that DNA methylation plays critical
roles in mammalian development.
DNAmethylation is also important for both stem cell dif-
ferentiation and cellular reprogramming. In differentia-
tion, dynamic DNA methylation changes are critical for
lineage specification as a wave of de novo methylation
takes place to silence pluripotency genes and establish tis-
sue-specific methylation patterns (Hawkins et al., 2010;
Lister et al., 2009; Stadler et al., 2011). During reprogram-
ming, DNA methylation contributes to an epigenetic
barrier. Inhibiting the activities of DNMTs with 5-aza-
cytidine (AzaC) or knocking down DNMT1 promotes
partially reprogrammed cells into a fully reprogrammed
state (Mikkelsen et al., 2008). Meanwhile, a wave of de
novo methylation also occurs during reprogramming36 Stem Cell Reports j Vol. 2 j 36–43 j January 14, 2014 j ª2014 The Authorwhereby tissue-specific genes and partially methylated
domains (PMDs) become hypermethylated (Doi et al.,
2009; Lister et al., 2009, 2011).
Inducedpluripotent stemcells (iPSCs) have the character-
istics of human embryonic stem cells (hESCs), and many
studies have investigated the similarities between iPSCs
and hESCs, including genome stabilities, transcriptome
(Chin et al., 2009; Guenther et al., 2010; Newman and
Cooper, 2010;Wang et al., 2011) and histonemodifications
(Guenther et al., 2010), and DNA methylation (Bock et al.,
2011; Doi et al., 2009; Kim et al., 2010; Lister et al., 2011;
Ohi et al., 2011; Ruiz et al., 2012). These studies revealed
both similarities and differences in the properties of iPSCs
and hESCs. DNA methylation in iPSCs has been reported
to acquire irregular methylation patterns while retaining
some memory of somatic cells during the reprogramming
process, thus exhibiting a methylation profile unique to
iPSCs (Bock et al., 2011; Doi et al., 2009; Kim et al., 2010;
Lister et al., 2011; Ohi et al., 2011). However, because these
previous studies differed in the quantitation techniques,
genome coverage, and sample sizes employed, it remains
contentious whether iPSCs possess amethylation signature
that can be used to distinguish iPSCs from hESCs.
To address this issue, we systemically compared the
methylation profiles of a large number of human iPSCs
(hiPSCs) and hESCs from multiple labs to revisit the ques-
tion of whether hiPSCs have a unique CpG methylations
Figure 1. A Unique Signature Distinguishes hiPSCs, hESCs, and
Somatic Cells
(A) Clustering analysis of methylation profiling in 26,837 CpG sites
in hiPSCs, somatic cells, and hESCs assayed by the Illumina
Infinium platform.
(B) Heatmap representation of the 82 signature CpGs in 15 hiPSCs,
five hESCs, and five somatic cells. The blue box highlights CpGs that
underwent de novo methylation in hiPSCs.
(C) GO analysis of the signature genes (n = 66). The p values shown
were adjusted using the Benjamini-Hochberg method.
See also Figure S1 and Table S1.
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Methylation Differences between hESCs and hiPSCssignature. We identified a panel of 82 CpGs that can distin-
guish hiPSCs from hESCs with high accuracy. Remarkably,
12 signature CpG sites tended to be hypermethylated
compared with both somatic cells and hESCs, suggesting
that thesemethylation signatures are not a form of residual
somatic epigenetic memory. Hypermethylation of these 12
sites is partially disrupted in DNMT3B-deficient hiPSCs,
consistent with the function of DNMT3B for de novo
methylation during reprogramming. Together, our results
demonstrate a robust hiPSC molecular signature that is
partially a consequence of DNMT3B-mediated de novo
methylation during reprogramming.RESULTS
A Unique DNA Methylation Signature Distinguishes
hiPSCs from hESCs and Somatic Cells
In previous reports, investigators have debated whether
hiPSCs exhibit a unique CpG methylation profile due to
either residual somatic cell memory or aberrant methyl-
ation in select domains when compared with hESCs. In
this study, we investigated this topic by analyzing CpG
methylation in a large number of pluripotent cell samples
(n = 269) from multiple labs, thus increasing the power of
the statistical analyses. Using Illumina Infinium BeadChip
assays, we first examined themethylation profiles of 25 cell
lines, including five hESCs, five parental somatic cells, and
15 lines of hiPSCs covering hiPSCs generated by both
vector-containing and vector-free methods. Globally, hier-
archical clustering analysis demonstrated that hiPSCs are
highly similar to hESCs, but distinctively different from
somatic cells (Figure 1A). To identify differential methyl-
ation between hiPSCs and hESCs, we used a statistically
stringent cutoff from Illumina’s custom model (see Experi-
mental Procedures) and required an absolute methylation
difference (delta-beta) of 0.3. We found that the methyl-
ation profiles from 82 CpG sites in 66 genes can effectively
group hiPSCs separately from either hESCs or parental
somatic cells (Figure 1B; Table S1 available online). Gene
Ontology (GO) analysis revealed that the signature genes
were associated with epidermal cell differentiation and
keratinization (Figure 1C). Interestingly, comparisons of
the hiPSC methylation signature among hESCs, hiPSCs,
and somatic cells revealed that the hiPSCs’ methylation
pattern often resembled that of somatic cells, except at 12
CpG sites that appeared to be uniquely hypermethylated
compared with both hESCs and somatic cells (Figure 1B).
This result suggested that the hiPSC methylation signature
consists of both residual somatic memory and specific CpG
sites that are subject to de novo methylation.
Ultimately, a robust signature should be able to
accurately discriminate between hiPSCs and hESCs inCell Reports j Vol. 2 j 36–43 j January 14, 2014 j ª2014 The Authors 37
Table 1. Classification Accuracy of Signature Genes by SVM
Data sets Platform No. of Samples (hiPSC/hESC)
Accuracy
FDR (%)Random 82 (%) Signature 82 (%)
Huang et al., current study Illumina 27k 20 (15/5) 81 100 4.55
Chou et al., 2011 Illumina 27k 31 (20/11) 69 96 0.01
Nazor et al., 2012 Illumina 27k 163 (45/118) 83 97 0.01
Nazor et al., 2012 Illumina 450k 47 (29/18) 82 97 0.31
Lister et al., 2009, 2011; Laurent et al., 2010;
Chodavarapu et al., 2010
WGBS 8 (5/3) 68 94 7.10
Total 269 (114/155)
The FDR was determined by computing the accuracy of randomly selected 82 CG sites (n = 20,000) to generate a background (or null) distribution, and then
finding the portion of the distribution that was greater than the observed accuracy of the signature sites.
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Methylation Differences between hESCs and hiPSCsindependent data sets regardless of the laboratory of origin
or the quantitation method used. Although hierarchal
clustering is one way to visualize how multiple samples
are grouped, we turned to more robust and quantitative
classification methods. To provide an unbiased estimate
of predictive accuracy for cell type, we used a leave-one-
out analysis in which the support vector machine (SVM)
learning model was fit on all but one sample and its predic-
tion was related to the truly observed cell type of the
left-out sample (see Experimental Procedures). Using other
DNA methylation data available in the public domain, we
consistently found that our signature CpGs could signifi-
cantly improve accuracy over randomly selected CGs for
identifying hiPSCs and hESCs. Although randomly
selected CGs tended to have a relatively high accuracy,
this appeared to be related to the level of hESC or hiPSC
skew in the data set (data not shown). Nevertheless, in
general, we observed correct classification of >95% of the
samples with a false discovery rate (FDR) of <0.05. The re-
sults of the external validations are summarized in Table 1.
We found that our panel of CG signature sites was able to
accurately discriminate between hiPSCs and hESCs despite
the varying sample sizes among different studies. For
example, we analyzed an independently derived Infinium
27k BeadChip data set that profiled DNA methylation in
20 hiPSCs and 11 hESCs (Chou et al., 2011), and showed
a classification accuracy of 96%. Another study using the
same platform examined 42 and 115 normal hiPSCs and
hESCs (Nazor et al., 2012). In this larger data set, we could
still accurately distinguish 97% of the hiPSCs and hESCs.
Together, these results indicated that the methylation
signature is robust to sample size sampling error.
Remarkably, our DNA methylation signature was also
able to accurately discriminate between hiPSCs and hESCs
regardless of the quantitation platform or technique used.
In a data set compiled using the Infinium 450k BeadChip38 Stem Cell Reports j Vol. 2 j 36–43 j January 14, 2014 j ª2014 The Authorsystem, we examined DNA methylation in 29 hiPSCs and
18 hESCs (Nazor et al., 2012). Interestingly, although
only 70 of the 82 signature probes were shared between
the two Illumina BeadChip platforms, these 70 probes
were still able to discriminate hiPSCs from hESCs with
97% accuracy. Next, we tried to cross-reference our signa-
ture CpGs with publically available genome-wide bisulfite
sequencing data sets. Although the reduced representation
bisulfite sequencing (RRBS) method is a cost-effective way
to sample 3 million CpGs in the human genome (Bock
et al., 2011; Ziller et al., 2011), we found that RRBS coverage
had low overlap with the 82 signature CG sites (35 loci
[40%] were detected) and was not ideal for cross-refer-
encing. We therefore turned to whole-genome shotgun
bisulfite sequencing data sets and curated a total of five
hiPSCs and three hESCs generated from three separate
labs (Chodavarapu et al., 2010; Laurent et al., 2010; Lister
et al., 2009, 2011). Strikingly, methylation quantitation
of the 82 signature sites through bisulfite sequencing could
also separate hiPSCs from hESCs with 95% accuracy.
Altogether, we analyzed 114 hiPSCs and 155 hESCs
collected from multiple labs, and these results indicated
that the identified CpG signature in our study is robust
and can be broadly used to make a distinction between
hiPSCs and hESCs.
Pairwise Comparisons of Promoter CpG Methylation
betweenhiPSCs and Somatic Cells Reveal aWave of De
Novo Methylation during Reprogramming
Because different somatic cells could have different tissue-
and cell-specific methylation patterns, we were interested
in dissecting the precise methylation changes during the
derivation of each iPSC line. We therefore performed a
pairwise comparison in each CpG site between three pairs
of hiPSCs and their parental somatic cells generated in
our lab. We first identified genes that exhibited statisticallys
Figure 2. Pairwise Comparison between Parental Somatic Cells and hiPSCs Reveals Alterations of Promoter Methylation in
Reprogramming and Correlation with Gene Expression
(A) Global view of DNA methylation changes during the reprogramming of parental somatic cell lines to hiPSCs. Using a delta-beta > 0.3
(increase in methylation) or <0.3 (decrease in methylation), we compiled the pie chart after comparing 26,837 CpG sites in 14,512 genes
for each pair of somatic cells and hiPSCs.
(B) Global methylcytosine levels as measured by HPLC-MS (n = 3 per sample). *p < 0.05 by Student’s t test.
(C) Status of gene-expression changes between hiPSCs and somatic cells for the gene promoters showing increased methylation in hiPSCs.
(D) GO analysis of genes with de novo methylation and decreased expression. The GO term is on the y axis and the p value indicating
significance is on the x axis. The p values of GO terms that are overrepresented in the data set are colored in red; p values of under-
represented or depleted GO terms are colored in green (Benjamini-Hochberg adjusted p value < 0.05).
See also Table S2.
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Methylation Differences between hESCs and hiPSCssignificant changes in methylation pattern using a delta-
beta value ofR0.3 or a cutoff of%0.3. Our data indicated
that 7%–14% of gene promoters underwent methylation
changes during direct reprogramming (Figure 2A), and 3.5-
to 6-fold more gene promoters exhibited an increase in
methylation than showed a decrease in methylation. This
result is in line with previous observations describing a
large number of hypermethylated promoters during
reprogramming (Nishino et al., 2011), including hyperme-
thylation at MEG3, PEG3, ZIM2, and other imprinted loci
(Nazor et al., 2012). Indeed, high-performance liquid chro-
matography mass spectrometry (HPLC-MS) showed an
overall increased level of DNA methylation in hiPSCs
compared with parental somatic cells (Figure 2B). Notably,
of the gene promoters with significant methylation
changes during reprogramming (1,000), 11 (or 1%) were
also associated with the hiPSC signature. Thus, a small
portion of the hiPSC signature arises from global methyl-Stemation changes during the reprogramming process, whereas
the remaining portion of signature CpG sites are associated
with somatic epigenetic memory.
By cross-referencing gene-expression profiles between
hiPSCs and parental somatic cells, we found that 60%–
75% of de novo methylation genes showed a significant
reduction of gene expression (FDR < 1010) or not ex-
pressed in hiPSCs (Figure 2C; Table S2). The increased
methylation levels at promoter CpG sites in hiPSCs were
confirmed by conventional bisulfite sequencing analysis
(Figure S1). In total, 151 genes showed hypermethylation
at promoter CpG sites and were also suppressed in all three
pairwise comparisons. GO analysis indicated that these
silenced genes were enriched for the genes required for
specific functions such as immune system process and
receptor activity (Figure 2D), consistent with a previous
report (Nishino et al., 2011). These silenced genes were
also depleted from genes involved in housekeepingCell Reports j Vol. 2 j 36–43 j January 14, 2014 j ª2014 The Authors 39
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Methylation Differences between hESCs and hiPSCsfunctions such as intracellular membrane organelle,
cellular metabolic process, and regulation of transcription
(Figure 2D).
In addition to global hypermethylation, some of the
methylation signature sites (n = 12) were also uniquely
hypermethylated in hiPSCs, but hypomethylated in both
somatic cells and a portion of hESCs (Figure 1B). Remark-
ably, these 12 sites were consistently hypermethylated in
hiPSCs comparedwith hESCs in independent data sets (Fig-
ure 3A), confirming that these sites tended to show unidi-
rectional differential methylation. However, on several
occasions, we foundheterogeneity in themethylation level
at these 12 loci in hESCs (Figure S2). Interestingly, hESCs
from the Nazor et al. (2012) data set revealed that cell lines
from the CM, ESI, FES, SIVF, and UC06 series tended to be
hypermethylated, whereas the HES, WA, and MEL series
tended to be hypomethylated (Figure S2C). These differ-
ences did not appear to be laboratory dependent, since
cell lines such as WA09 (also referred to as H9) cultured in
four separate labs were consistently hypomethylated at
these sites. Closer inspection of the Nazor et al. (2012)
data sets revealed a mild inverse relationship between cell
passage number and hypermethylation status (r = 0.42,
p < 107; Figure S2D). Thus, prolonged culture appears to
attenuate the hypermethylation at these 12 sites in a
portion of hESCs. However, we have not analyzed methyl-
ation data of hiPSCs in extended culture (Table S3), so we
cannot preclude the possibility that these 12 sites would
show a similar epigenetic drift in long-term culture.
Hypermethylation by DNMT3B Contributes to the
Panel of Methylation Signatures
Because Dnmt3B is more dramatically upregulated in
hiPSCs when compared with the levels of Dnmt3A and
Dnmt1 (Stadtfeld et al., 2008), we hypothesized that
DNMT3B may play a major role in de novo methylation
in hiPSCs. To test this hypothesis, we generated hiPSCs
from skin fibroblasts of patients with ICF (immunodefi-
ciency, centromere instability, and facial anomalies) syn-
drome who carried double heterozygous point mutations
in the catalytic domain of DNMT3B, and mapped the
methylome for two ICF hiPSC lines at basepair resolution
via whole-genome shotgun bisulfite sequencing. By cross-
referencing other whole-genome bisulfite sequencing
data sets, we confirmed that our 12 hypermethylation
signature sites were hypomethylated in parental somatic
cells, but hypermethylated in hiPSCs (Figure 3B). In the
ICF hiPSCs, methylation levels at these 12 sites were gener-
ally reduced, but showed some variability (Figure 3B). Five
of the 12 sites were consistently hypomethylated, suggest-
ing that DNMT3B contributes to de novomethylation in at
least some of these 12 CpG targets.We validated four out of
five sites in additional ICF hiPSCs subclones using methyl-40 Stem Cell Reports j Vol. 2 j 36–43 j January 14, 2014 j ª2014 The Authoration-specific PCR (MSP) (Figure S2E). Remarkably, all 12
CpG sites were located in regions of low CG density (Fig-
ure 3C). In addition, by leveraging various histone peaks
found in H1 ESCs, we found that these 12 CpG sites tended
to also be devoid of histone marks (Figure 3C).
We next sought to determine how DNMT3B deficiency
affects other hiPSC DNA methylation signatures reported
in the literature. For example, kilobase hotspots for aberrant
hypermethylation were previously identified in hiPSCs
compared with hESCs (Lister et al., 2011). We found that
all hotspot hypermethylated DMRs were hypomethylated
in ICFhiPSCs anddisplayed aprofile similar to thatofhESCs
(Figure 3D). Furthermore, eight out of nine previously iden-
tified core signature genes with aberrant promoter hyper-
methylation in hiPSCs (Ruiz et al., 2012) were found to be
hypomethylated in ICF hiPSCs (Figure 3E). Notably,
TCERG1L was consistently identified as an aberrantly hy-
permethylated gene in two previous studies and confirmed
in our current study (Lister et al., 2011; Ruiz et al., 2012).
Interestingly, gene-expression profiling of ICF hiPSCs and
control hiPSCs showed that TCERG1L promoter hyperme-
thylation is associated with gene repression (Figure 3F).
Together, our data suggest that DNMT3B contributes to
aberrant hypermethylationduring cellular reprogramming.DISCUSSION
Up to now, it was not clear whether hiPSCs have distinct
transcriptomes and methylomes when compared with
hESCs. Although one initial study reported the presence
of iPSC-specific gene expression in a small number of iPSCs
(Chin et al., 2009), several other studies argued that, at least
on the individual gene-expression level, there are large
variations among separate data sets (Guenther et al.,
2010; Newman and Cooper, 2010). Recognizing the limita-
tions for analyses based on individual genes, we previously
utilized weighted gene coexpression network analysis
(WGCNA) to identify functional modules that are distinct
between iPSCs and ESCs (Wang et al., 2011). We further
showed that one of these functional modules was inversely
correlated with the level of DNA methylation in gene
promoters, suggesting specific methylation changes in
the hiPSCs. However, the module (n = 751 genes) had a
small overlap (2 out of 66) with the signature genes identi-
fied in this study (TCERG1L and TSPYL5).
Because iPSCs exhibit a significant increase in genome-
wide methylation when compared with parental somatic
cells, we suspected that de novo methylation plays an
important role in establishing a unique iPSC methylation
signature. By comparing methylation patterns in mutant
ICF-iPSCs, we indeed found some altered methylation sig-
natures, suggesting that DNMT3B contributes to de novos
Figure 3. Wave of De Novo Methylation during Reprogramming by DNMT3B
(A) Boxplot of the average methylation levels for the 12 sites that tend to be hypermethylated in hiPSCs. The + sign denotes outliers. ESC1
denotes hESCs from the CM, ESI, FES, SIVF, UC06, and MIZ series, and ESC2 denotes hESCs from the HES, WA, MEL, and MIV series.
(B) Heatmap of the 12 CpGs through bisulfite sequencing. The legend represents raw methylation levels.
(C) Bar graph of the percentage of sites that were positive for the labeled attributes.
(D) Heatmap of CG methylation levels in previously identified domains (1–6 kb) of aberrant hypermethylation in iPSCs from Lister
et al. (2011).
(E) Bar graph of average CG methylation in the promoter (TSS ± 500 bp) of core iPSC signature genes from Ruiz et al. (2012). Error bars
represent SD of the mean CG methylation in samples from WGBS data sets as described in Table 1.
(F) Genome browser view of expression as measured by RNA sequencing (top four tracks) and CG methylation levels (red tracks) at the
signature gene, TCERG1L. Note the selective hypomethylation at the proximal promoter associated with increased gene expression.
See also Figure S2 and Table S3.
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Methylation Differences between hESCs and hiPSCsmethylation during reprogramming. In particular, we iden-
tified five signature CpGs (out of the 82 CpG signature
sites) that undergo DNMT3B-mediated de novo methyl-
ation. This conclusion was also extended to hypermethyla-
tion signatures identified by others (Lister et al., 2011; Ruiz
et al., 2012).
Our methylation signature is different from what was
previously identified by either microarray or high-
throughput sequencing analysis. Earlier studies suffered
primarily from limited sample sizes due to the costly
approach required to measure genome-wide DNA methyl-
ation levels on a comprehensive scale. Several previous
studies using RRBS attempted to verify reported signatures
in the literature and found a lack of reproducibility (Bock
et al., 2011; Ziller et al., 2011), arguing instead for varia-
tions in iPSCs. Because RRBS covers 10% of human CpG
sites and is biased toward regions of high CpG density, it
is possible that the method could not fully detect the
regions that were consistently different in iPSCs. A more
recent study by Ruiz et al. (2012) using the bisulfite
sequencing padlock probe (BSPP) system identified nine
signature genes that distinguish hESCs from hiPSCs. On
average, BSPP covers 500,000 CpGs in the human genome
(1% of all human CpG sites); however, these sites have
low overlapwith the Infinium27k array (25% shared sites
within 100 bp). Moreover, when we compared our list of
signature CG sites with other signatures in the literature,
we found minimal overlap (Doi et al., 2009; Lister et al.,
2011). Nevertheless, it is still unclear whether this low over-
lap is due to incompatible coverage or lack of sample size
for robust delineation of an accurate signature. For
example, Lister et al. (2011) initially identified hundreds
of CG-DMRs in iPSCs, only a small fraction of which could
be confirmed in multiple cell lines, suggesting that the
number of sites is gradually reduced as the sample size be-
comes larger. By contrast, although we identified a methyl-
ation signature using 25 cell lines, we were able to validate
these signatures in 249 other samples, demonstrating that
our signature comprises a core set of CpG sites that can reli-
ably distinguish iPSCs, hESCs, and somatic cells. Overall,
we suggest that although a definitive signature whereby a
given site is always differentially methylated between the
two cell typesmay not exist, a panel of CpG sites represent-
ing loci that tend to be differentially methylated is suffi-
cient to segregate iPSCs and hESCs. Thus, this panel of
CpG methylation signatures in iPSCs may be useful as a
molecular biomarker for classifying iPSCs in the future.EXPERIMENTAL PROCEDURES
Briefly, hiPSCs were generated from IMR90, CCD-1097SK, BJ1, and
NPC cells derived from 11-week-old fetal brain using retroviral
expression of OCT4, SOX2, KLF4, and c-MYC or OCT4, NANOG,42 Stem Cell Reports j Vol. 2 j 36–43 j January 14, 2014 j ª2014 The AuthorKLF4, and LIN-28. This study of hESCs and hiPSCs was approved
by theUCLAEmbryonic StemCell ResearchOversightCommittee.
We used the HumanMethylation27 DNA Analysis BeadChip from
Illumina to interrogate 26,837 CpG sites over 14,152 genes. Full
experimental procedures and data analysis are available in the
Supplemental Experimental Procedures.
ACCESSION NUMBERS
The microarray data have been deposited in the Gene Expression
Omnibus under accession number GSE42043.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and three tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2013.11.003.
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